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We report here a case of recurrent paratyphoid fever A with hepatitis A co-infection in a patient with chronic hepatitis
B. A 26-year-old male patient, who was a hepatitis B virus carrier, was co-infected with Salmonella enterica serovar
Paratyphi A and hepatitis A virus. The recurrence of the paratyphoid fever may be ascribed to the coexistence of
hepatitis B, a course of ceftriaxone plus levofloxacin that was too short and the insensitivity of paratyphoid fever A to
levofloxacin. We find that an adequate course and dose of ceftriaxone is a better strategy for treating paratyphoid fever.
Furthermore, the co-infection of paratyphoid fever with hepatitis A may stimulate cellular immunity and break
immunotolerance. Thus, the administration of the anti-viral agent entecavir may greatly improve the prognosis of this
patient with chronic hepatitis B, and the episodes of paratyphoid fever and hepatitis A infection prompt the use of
timely antiviral therapy.
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More than 1 month before admission to our hospital, a 26-
year-old male worker was diagnosed with paratyphoid fever
due to a high fever of up to 40°C that was accompanied by
dizziness, fatigue, a cough with some sputum and discom-
fort in the periumbilical area. Salmonella Paratyphi A was
isolated from his blood; therefore, ceftriaxone and levoflox-
acin were co-administered for 7 days, and his temperature
returned to normal. However, approximately 10 days after
completing the treatment, he presented to a local hospital
because of a recurrent high fever. The patient was given an
intravenous levofloxacin infusion with little improvement
in his condition, and routine blood tests revealed a white
blood cell (WBC) count of 5.5 × 109/L with 63% neutro-
phils and a platelet count of 68 × 109/L. He was then trans-
ferred to our hospital. The patient had a history of hepatitis
B virus beginning in childhood.
Upon admission, a physical examination revealed spleno-
megaly, but no bradycardia [temperature (T): 39.2°C; pulse
rate (P): 99 times/min]. Laboratory studies revealed a de-
creased WBC count of 3.91 × 109/L with 63% neutrophils* Correspondence: beijia7410@163.com
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unless otherwise stated.and 0% eosinophils. His ALT, AST, and lactate dehydro-
genase (LDH) levels were 927 U/L, 876 U/L and 224 U/L,
respectively, and hepatitis B virus (HBV) DNA was present
at 1.38 × 105 IU/L. Blood cultures were performed twice,
and a B-mode ultrasound revealed splenomegaly.
The patient received 0.3 g of levofloxacin via injection
twice a day, but 2 days later, his temperature remained ele-
vated, at approximately 39°C. Therefore, a bone marrow
puncture was performed for a routine examination and cul-
ture. Viral markers for hepatitis C and E, cytomegalovirus
and the Epstein-Barr virus were negative, but the marker
for hepatitis A was positive (immunoglobulin M, twice;
rheumatoid factor was negative). S. Paratyphi was isolated
from his blood but not from his bone marrow, and the sus-
ceptibility test indicated that this species of bacteria had an
intermediate susceptibility to ciprofloxacin. A bone marrow
picture revealed no abnormalities. Therefore, a 2-g cef-
triaxone injection twice a day was added to his treat-
ment in addition to thymosin α1, which was given once
every other day. Furthermore, the nucleotide analogue
entecavir was given concurrently to inhibit the HBV DNA.
The temperature of the patient returned to normal after
4 days of treatment with levofloxacin and ceftriaxone,
and he progressively recovered his appetite and sense of
well being.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vealed a leucocyte count of 6.03 × 109/L (40.8% neutrophils
and 4.8% eosinophils), total bilirubin and direct bilirubin
counts that were within the normal range, an ALT level of
71 U/L and an AST level of 51 U/L. The blood and stool
cultures were negative, and the patient was discharged in
good condition. Three months later, he came back for a
follow-up. The laboratory results were as follows: liver
function was indicated by an ALT level of 145 U/L, anti-
hepatitis A virus immunoglobulin M (anti-HAV IgM) was
negative, and the HBV DNA was below the limit of detec-
tion. Six months later, his liver function totally recovered.
Discussion
Paratyphoid fever A is a communicable disease that is
transmitted through the faecal-oral route. This disease
usually presents with a mild clinical manifestation that is
shorter in duration and less resistant to antimicrobials
than typhoid fever. The occurrence of this disease has
been reported less frequently both globally and in China;
however, the incidence of paratyphoid fever A has recently
surpassed that of typhoid fever [1,2]. Here, we present the
case of a 26-year-old man with chronic hepatitis B who
was co-infected with recurrent paratyphoid fever A and
hepatitis A; this case differs from previously reported cases
mainly in two aspects.
As an intracellular pathogen, Salmonella Paratyphi is
predominantly killed via the mononuclear phagocytes in-
volved in cellular immunity. The recurrence of paratyphoid
fever is closely correlated with a deficiency in cellular
immunity, an inadequate dose or duration of antimicro-
bial treatment and a decreased susceptibility to antibi-
otics. Other factors, including undiagnosed, deep-seated
diseases such as osteomyelitis and aortitis, are also likely
to be critical for relapse [3]. The patient in this study suf-
fered from chronic hepatitis B, and the HBV may have im-
paired cell-mediated immunity and favoured the relapse
of Salmonella septicaemia. A previously reported case
revealed that tuberculosis, which is caused by another
intracellular pathogen, also predisposed a patient to the re-
currence of Salmonella sepsis by interfering with the ability
of macrophages to kill Salmonella [4]. During the first epi-
sode of paratyphoid fever for the patient in this study, both
ceftriaxone and levofloxacin were used, but the course of
treatment was only 7 days. These 2 drugs are the first line
medications for treating adult paratyphoid fever. Although
a short course of ciprofloxacin has been clinically con-
firmed to be efficient for curing typhoid, a longer course is
likely required to cure paratyphoid because of the high rate
of relapse for this disease [5,6]. When the patient’s fever
returned, levofloxacin was used, which penetrates well and
is usually very active against Salmonella species. However,
the drug susceptibility test revealed that the isolate had an
intermediate susceptibility to fluoroquinolones and wassusceptible to ceftriaxone. Salmonellae that are less suscep-
tible to fluoroquinolones have been frequently reported
globally, especially in developing countries such as India
and China, and this reduced susceptibility is related to a
single gyrA mutation and an additional mutation in parC
[ciprofloxacin minimum inhibitory concentration (MIC) ≥
0.5 mg/L] [7-9]. Treatment failures have been described in
strains that display decreased ciprofloxacin susceptibility
[10]; therefore, alternative therapeutic strategies, such as
arithromycin (1 g on the first day and 500 mg per day
afterwards) [11] or high-dose ceftriaxone (4 g per day), are
recommended for these patients. Considering the possible
adverse effects of gastrointestinal disturbance and hepatic
toxicity due to arithromycin, we adopted the combination
of ceftriaxone (4 g per day) plus levofloxacin (0.6 g per
day) for 12 days. Re-examination of the blood test results
revealed normal WBC and eosinophil counts. Further-
more, the follow-up after 3 months did not indicate a re-
lapse. Therefore, adequate cellular immunity, appropriate
drug doses and a proper course of treatment are all crucial
for healing paratyphoid fever. An 8-time recurrence of
paratyphoid fever has been previously reported that was
largely due to poor drug administration [4].
Another interesting point regarding this case is the alter-
ation of the liver function. Three factors may have caused
liver damage: Salmonella, the hepatitis A virus and HBV.
The co-infection of paratyphoid fever with hepatitis A
and/or E has been frequently reported, and in these cases,
the aminotransferase levels were sharply elevated or jaun-
dice appeared [12-14]. The incubation periods for hepatitis
A and paratyphoid A are 5–50 days and 2–15 days, re-
spectively. Therefore, these 2 diseases may occur simultan-
eously. It has been reported that the ratio of ALT to LDH
may distinguish hepatitis caused by Salmonella (<4.0) and
acute viral hepatitis (>5.0) [15], and the ration here was
4.13. When the patient was examined upon admission to
our hospital, it is likely that his aminotransferase levels
had already decreased because hepatitis A is usually a self-
limiting illness. This patient, who had an intermediate
increase in his HBV-DNA level, benefited because an
optimal time for treating the chronic hepatitis B appeared.
This patient was a young man who was in a state of im-
mune tolerance. The co-infection of Salmonella and
hepatitis A stimulated his cellular immune system, and
the prominent elevation of the ALT and AST levels sug-
gested that he would respond well to anti-viral therapy.
The proper, early administration of anti-viral treatment to
patients who have been infected with HBV since childhood
will greatly decrease the possibility of developing cirrhosis
and hepatocellular carcinoma (HCC). In this case, a drug
with high-efficacy and a low gene-resistance barrier was
more appropriate for this patient. One month after the ad-
ministration of entecavir, the level of HBV DNA in the pa-
tient decreased below the detection limit. Three months
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than when he was examined before being discharged,
which suggested a good response to the entecavir treat-
ment. At this point, his anti-HAV IgM level was already
negative.
Many authors have reported that the elevation of ami-
notransferases in a patient with a Salmonella infection
may signal a co-infection with other Hepadnaviridae, such
as hepatitis A or E. All of these organisms are intracellular
pathogens, and cellular immunity is the main defence
mechanism for controlling these infections. In China, ap-
proximately 3 billion people who carry HBV, and these in-
dividuals suffer from the possibility of cellular immunity
dysfunction and deficiency. Therefore, they are susceptible
to infection by intracellular pathogens. The insults to the
liver due to concomitant infections are usually more se-
vere and can result in encephalopathy, liver failure or
renal failure. The case presented here only had an inter-
mediate level of liver dysfunction, which was likely due to
the detection time and his age. Another aspect of this co-
infection is that the concurrent infection with intracellular
pathogens, such as Salmonella and other acute hepatitis
viruses, may provide an earlier opportunity for these pa-
tients to clear the HBV with a timely anti-viral treatment
due to the activation of cellular immunity, which breaks
the immunotolerance barrier.
Nevertheless, the coinfection of other contagious dis-
eases usually worsen the original disease,thus prevention
rather than treatment remains the crucial way for various
infectious diseases. Combination vaccines against typhoid
fever and hepatitis A are already available for susceptible
people [16,17].
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